SYMPOSIUM ON
Immunomodulation
in Cancer & Regeneration
PREVIOUS EDITIONS
Speakers 2019
Symposium on Immunomodulation in Cancer and Regeneration
25 JUNE 2019
Jérôme Galon
Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, France
Dr Jérôme Galon is first class Director of Research at INSERM (French National Institute of Health and Medical Research) and head of an INSERM laboratory (INSERM UMRS1138, Integrative Cancer Immunology) at the Cordeliers Research Center in Paris, France. Dr. Galon was trained as an immunologist at the Pasteur Institute and at the Curie Institute (Paris, France) and did postdoctoral work at the National Institute of Health (NIH), in Bethesda (USA) between 1997 and 2001. He is the co-founder of the company, HalioDx, and is the Chairman of its scientific council. He is associate Director and co-founder of the European Academy of Tumor Immunology (EATI), Board Director of Society for Immunotherapy of Cancer (SITC, USA), member of AAI, SFI, and AACR. His work aims at a better understanding of the tumor microenvironment and the dynamics of the immune response in human tumors. His laboratory has identified and demonstrated the importance of the immune contexture against cancer. He defined the Immunoscore as a new method for routine clinical assessment of prognosis of patients with cancer.
Luís Graça
IMM– Instituto De Medicina Molecular, Portugal
Dr Luís Graça is a group Leader at iMM Lisboa since 2005 and Associate Professor at Faculdade de Medicina da Universidade de Lisboa. He obtained his Medical Doctor degree in 1995, from Faculdade de Medicina da Universidade de Lisboa (FMUL) and his PhD (2002) in Immunology from the University of Oxford, UK. He was Post-doctoral researcher at University of Oxford, UK, and at University of Western Australia, Perth. He has received several prizes, including iMM Innovators, NEDAI Prize in Autoimmunity Research, Young Entrepreneur Award 2010, from ANJE, an Honorary mention in the ISCTE-IUL MIT-Portugal Venture Competition, BES National Innovation Award for Health Technologies, and the Prof. Heimburger Award in Coagulation Diseases, CSL Behring, 2009. His lab studies mechanisms able to induce and maintain immune tolerance. He studies diseases, or animal models of human pathologies, where the immune system has an inappropriate action, such as in autoimmunity, transplantation or allergy.
Mike Dustin
The Kennedy Institute of Rheumatology, University of Oxford, United Kingdom
Prof. Dustin has a B.A. in Biology from Boston University (1984) and a Ph.D. in Cell and Developmental Biology from Harvard University (1990). He completed post-doctoral training with Stuart Kornfeld at Washington University School of Medicine (1993). Dr. Dustin led his own group at the Department of Pathology at Washington University School of Medicine under Steve Teitelbaum and Emil Unanue from 1993 to 2000. While at Wash University, he led a collaborative group in discovering requirements for the T cell immunological synapse with Andrey Shaw, Paul Allen, Mark Davis (Stanford) and Emil Unanue. He moved his lab to the Skirball Institute of Biomolecular Medicine at New York University School of Medicine in 2001. He was director of the NIH funded Nanomedicine Center for Mechanobiology from 2009-2014. He moved to the Kennedy Institute of Rheumatology at the University of Oxford in 2013 supported by a Principal Research Fellowship from the Wellcome Trust. Hi work has contributed to describe and define the requirements for the T cell immunological synapse. He is now focused on further advancing studies on the immunological synapse and on translation to treatment of human diseases.
